loading...| Preferred Name |
Regorafenib |
|
| Synonyms |
BAY 73-4506 Regorafenib Anhydrous REGORAFENIB ANHYDROUS 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide Regorafenib |
|
| Definitions |
The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C78204 |
|
| Accepted_Therapeutic_Use_For |
hepatocellular carcinoma (HCC) |
|
| CAS_Registry |
755037-03-7 |
|
| Chemical_Formula |
C21H15ClF4N4O3 |
|
| code |
C78204 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C179531 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc PCDC |
|
| DEFINITION |
The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling. |
|
| Display_Name |
Regorafenib |
|
| FDA_UNII_Code |
24T2A1DOYB |
|
| FULL_SYN |
BAY 73-4506 Regorafenib Anhydrous REGORAFENIB ANHYDROUS 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide Regorafenib |
|
| Has_Target |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C28496 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17328 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17322 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C26203 |
|
| Is_Value_For_GDC_Property | ||
| label |
Regorafenib |
|
| Legacy Concept Name |
Multitargeted_Receptor_Tyrosine_Kinase_Inhibitor_BAY_73-4506 |
|
| Maps_To |
Regorafenib |
|
| NCI_Drug_Dictionary_ID |
595192 |
|
| PDQ_Closed_Trial_Search_ID |
595192 |
|
| PDQ_Open_Trial_Search_ID |
595192 |
|
| Preferred_Name |
Regorafenib |
|
| prefixIRI |
Thesaurus:C78204 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C2980094 |
|
| subClassOf |